ARVIDAL

Classe 5 — Outros setores

Pharmaceutical preparations; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections or diseases caused by viruses, namely by intravenous, intramuscular, oral, sublingual, buccal, nasal, topical administration and/or administered by inhalation, by spraying or by nebulisation in patients; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viruses, seasonal and pandemic influenza A and B viruses, seasonal coronaviruses (Alpha-, Beta-, Gamma- and Deltacoronaviruses), severe acute respiratory syndrome (SARS-CoV) coronaviruses and Middle East respiratory syndrome (MERS) coronavirus, adenoviruses, respiratory syncytial viruses, parainfluenza viruses, rhinoviruses, human metapneumoviruses, bocaviruses, and infections of combined etiology (multiple viral infections); pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention, and treatment of acute respiratory infections caused by viral infections of the upper and lower respiratory tract; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of tissue lesions in the lungs caused by severe pulmonary infectious diseases; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of complications arising from or caused by viral infections; pharmaceutical preparations and pharmaceutical products for the prevention and treatment of acute respiratory infections, acute respiratory viral infections of unknown origins and complications arising from or caused by viral infections.;